hotspot -WSS

hotspot

author：focus 2025-09-06 08:25:09 - browse：4

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： President Biden's budget: Here's what you might have missed

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Pushing for an NIH office for post

FDA advisers back CAR

focus

hotspot

entertainment

Supreme Court strikes down use of affirmative action

Travis Kelce and the trap of celebrity vaccine endorsements

Moonlake's readout produced a cash windfall. Risks remain

EPA limits use of carcinogenic gas for sterilizing medical devices

Walensky prepares to leave CDC — and Congress — behind

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

How to save PrEP access — and even expand it

Lung cancer screening guidelines updated for cigarette smokers

entertainment

FDA advisers back CAR

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

First U.S. drug developed to treat liver disease MASH is approved

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Life sciences investors close nearly $6 billion in new funds

Wikipedia

focus

explore

knowledge